Kesimpta, whose generic name is ofatumumab, is a medication primarily used to treat multiple sclerosis (MS), a chronic disease affecting the nervous system. It works by targeting specific immune cells called B-cells, which play a role in the abnormal immune response seen in MS. Because Kesimpta affects the immune system, one important concern is whether it can cause severe infections.
Kesimpta can increase the risk of infections, including serious ones, because it lowers the number of B-cells that help fight infections. By reducing these immune cells, the body’s ability to respond to bacteria, viruses, and other pathogens can be weakened. This means patients taking Kesimpta may be more vulnerable to infections that could become severe if not recognized and treated promptly.
In clinical studies and patient reports, infections such as upper respiratory tract infections (like colds), nasopharyngitis (inflammation of the nose and throat), and urinary tract infections have been observed. While many of these infections tend to be mild or moderate, there is a documented risk of more serious infections occurring in some patients. These serious infections can include pneumonia, herpes virus infections, and other opportunistic infections that take advantage of the weakened immune system.
The risk of severe infections with Kesimpta is not extremely high but is significant enough that doctors monitor patients closely. Patients are advised to report any signs of infection immediately, such as fever, chills, persistent cough, shortness of breath, unusual tiredness, or any other symptoms that suggest an infection. Early detection and treatment are crucial to prevent complications.
Because Kesimpta is administered by injection, there can also be injection-related reactions, which are generally mild to moderate but can sometimes complicate the overall treatment experience. These reactions are different from infections but are part of the medication’s safety profile.
Patients with a history of chronic infections, weakened immune systems, or those taking other immunosuppressive drugs may have an even higher risk of severe infections when using Kesimpta. Therefore, healthcare providers carefully evaluate each patient’s medical history before starting treatment and continue to monitor immune function during therapy.
In addition to infections, Kesimpta may cause other side effects, but the concern about severe infections is particularly important because infections can be life-threatening if not managed properly. Preventive measures, such as vaccinations before starting Kesimpta and avoiding exposure to contagious illnesses, are often recommended to reduce infection risk.
Overall, Kesimpta does have the potential to cause severe infections due to its immune-suppressing action, but with careful medical supervision, patient education, and prompt treatment of any infections, these risks can be managed. Patients should maintain regular communication with their healthcare providers and seek medical attention immediately if they experience symptoms suggestive of infection while on Kesimpta.
